invitrogen europe limited
invitrogen europe limited Company Information
Company Number
SC084330
Next Accounts
Sep 2025
Shareholders
invitrogen holdings limited
Group Structure
View All
Industry
Non-trading company
Registered Address
3 fountain drive, inchinnan business park, paisley, renfrewshire, PA4 9RF
Website
http://thermofisher.cominvitrogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of INVITROGEN EUROPE LIMITED at £0 based on a Turnover of £0 and 0.54x industry multiple (adjusted for size and gross margin).
invitrogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of INVITROGEN EUROPE LIMITED at £46.6k based on an EBITDA of £11k and a 4.24x industry multiple (adjusted for size and gross margin).
invitrogen europe limited Estimated Valuation
Pomanda estimates the enterprise value of INVITROGEN EUROPE LIMITED at £29.7b based on Net Assets of £22.8b and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Invitrogen Europe Limited Overview
Invitrogen Europe Limited is a live company located in paisley, PA4 9RF with a Companies House number of SC084330. It operates in the non-trading company sector, SIC Code 74990. Founded in August 1983, it's largest shareholder is invitrogen holdings limited with a 100% stake. Invitrogen Europe Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Invitrogen Europe Limited Health Check
Pomanda's financial health check has awarded Invitrogen Europe Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Invitrogen Europe Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
- Invitrogen Europe Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Invitrogen Europe Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Invitrogen Europe Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Invitrogen Europe Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 0%, this is a lower level of debt than the average (47.9%)
- - Invitrogen Europe Limited
- - Industry AVG
INVITROGEN EUROPE LIMITED financials
Invitrogen Europe Limited's latest turnover from December 2023 is 0 and the company has net assets of £22.8 billion. According to their latest financial statements, we estimate that Invitrogen Europe Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | -20,000 | -81,194,000 | |||||||||||||
| Operating Profit | 11,000 | -31,000 | -2,000 | -14,000 | -24,000 | -5,000 | -5,000 | -5,000 | -8,000 | -9,000 | -2,000 | -1,640,000 | -373,000 | 20,000 | 81,194,000 |
| Interest Payable | 24,000 | 69,000 | 37,000 | 264,000 | |||||||||||
| Interest Receivable | 266,000 | 49,000 | 3,000 | 12,000 | 5,000 | 90,000 | 80,000 | 90,000 | 3,140,000 | 8,015,000 | 6,985,000 | 13,842,000 | 11,123,000 | ||
| Pre-Tax Profit | 28,777,000 | 58,018,000 | -2,000 | 4,562,175,000 | -12,000 | -29,000 | 1,897,000 | 72,000 | 1,477,173,000 | 30,161,000 | 36,138,000 | 16,112,000 | 13,825,000 | 168,673,000 | |
| Tax | 189,000 | -3,871,000 | -4,964,000 | ||||||||||||
| Profit After Tax | 28,777,000 | 58,018,000 | -2,000 | 4,562,175,000 | -12,000 | -29,000 | 1,897,000 | 72,000 | 1,477,173,000 | 30,161,000 | 36,138,000 | 16,301,000 | 9,954,000 | 163,709,000 | |
| Dividends Paid | 4,562,186,000 | 5,057,000 | 272,257,000 | ||||||||||||
| Retained Profit | 28,777,000 | 58,018,000 | -2,000 | -11,000 | -12,000 | -29,000 | 1,897,000 | 72,000 | 1,472,116,000 | -242,096,000 | 36,138,000 | 16,301,000 | 9,954,000 | 163,709,000 | |
| Employee Costs | |||||||||||||||
| Number Of Employees | |||||||||||||||
| EBITDA* | 11,000 | -31,000 | -2,000 | -14,000 | -24,000 | -5,000 | -5,000 | -5,000 | -8,000 | -9,000 | -2,000 | -1,640,000 | -373,000 | 20,000 | 81,194,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | 22,756,126,000 | 22,756,126,000 | 22,678,454,000 | 22,604,320,000 | 22,495,370,000 | 21,554,282,000 | 6,993,338,000 | 6,993,338,000 | 6,201,659,000 | 6,201,659,000 | 1,311,052,000 | 1,311,052,000 | 1,311,052,000 | 1,311,052,000 | 261,387,000 |
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 22,756,126,000 | 22,756,126,000 | 22,678,454,000 | 22,604,320,000 | 22,495,370,000 | 21,554,282,000 | 6,993,338,000 | 6,993,338,000 | 6,201,659,000 | 6,201,659,000 | 1,311,052,000 | 1,311,052,000 | 1,311,052,000 | 1,311,052,000 | 261,387,000 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | 6,850,000 | 6,573,000 | 6,553,000 | 6,560,000 | 6,563,000 | 6,575,000 | 6,577,000 | 6,606,000 | 4,709,000 | 4,636,000 | 4,558,000 | 246,865,000 | 221,789,000 | 209,243,000 | 499,487,000 |
| Misc Debtors | 4,149,000 | 1,723,000 | 1,812,000 | ||||||||||||
| Cash | |||||||||||||||
| misc current assets | |||||||||||||||
| total current assets | 6,850,000 | 6,573,000 | 6,553,000 | 6,560,000 | 6,563,000 | 6,575,000 | 6,577,000 | 6,606,000 | 4,709,000 | 4,636,000 | 4,558,000 | 246,865,000 | 225,938,000 | 210,966,000 | 501,299,000 |
| total assets | 22,762,976,000 | 22,762,699,000 | 22,685,007,000 | 22,610,880,000 | 22,501,933,000 | 21,560,857,000 | 6,999,915,000 | 6,999,944,000 | 6,206,368,000 | 6,206,295,000 | 1,315,610,000 | 1,557,917,000 | 1,536,990,000 | 1,522,018,000 | 762,686,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 6,000 | 7,000 | 1,000 | ||||||||||||
| Group/Directors Accounts | 2,029,000 | 2,021,000 | 313,000 | ||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 8,000 | 8,000 | 6,000 | 11,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 210,000 | 237,000 | 1,573,000 | 12,569,000 | |
| total current liabilities | 8,000 | 8,000 | 6,000 | 11,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 6,000 | 217,000 | 2,266,000 | 3,595,000 | 12,882,000 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 8,000 | 8,000 | 6,000 | 11,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 2,000 | 6,000 | 217,000 | 2,266,000 | 3,595,000 | 12,882,000 |
| net assets | 22,762,968,000 | 22,762,691,000 | 22,685,001,000 | 22,610,869,000 | 22,501,930,000 | 21,560,854,000 | 6,999,912,000 | 6,999,941,000 | 6,206,365,000 | 6,206,293,000 | 1,315,604,000 | 1,557,700,000 | 1,534,724,000 | 1,518,423,000 | 749,804,000 |
| total shareholders funds | 22,762,968,000 | 22,762,691,000 | 22,685,001,000 | 22,610,869,000 | 22,501,930,000 | 21,560,854,000 | 6,999,912,000 | 6,999,941,000 | 6,206,365,000 | 6,206,293,000 | 1,315,604,000 | 1,557,700,000 | 1,534,724,000 | 1,518,423,000 | 749,804,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 11,000 | -31,000 | -2,000 | -14,000 | -24,000 | -5,000 | -5,000 | -5,000 | -8,000 | -9,000 | -2,000 | -1,640,000 | -373,000 | 20,000 | 81,194,000 |
| Depreciation | |||||||||||||||
| Amortisation | |||||||||||||||
| Tax | 189,000 | -3,871,000 | -4,964,000 | ||||||||||||
| Stock | |||||||||||||||
| Debtors | 277,000 | 20,000 | -7,000 | -3,000 | -12,000 | -2,000 | -29,000 | 1,897,000 | 73,000 | 78,000 | -242,307,000 | 20,927,000 | 14,972,000 | -290,333,000 | 501,299,000 |
| Creditors | -6,000 | -1,000 | 7,000 | -1,000 | 1,000 | ||||||||||
| Accruals and Deferred Income | 2,000 | -5,000 | 8,000 | 1,000 | 2,000 | -210,000 | -27,000 | -1,336,000 | -10,996,000 | 12,569,000 | |||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -266,000 | -49,000 | -3,000 | -12,000 | -3,000 | 24,000 | -1,902,000 | -80,000 | -91,000 | 242,094,000 | -22,587,000 | -16,493,000 | 275,487,000 | -412,500,000 | |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 77,672,000 | 74,134,000 | 108,950,000 | 941,088,000 | 14,560,944,000 | 791,679,000 | 4,890,607,000 | 1,049,665,000 | 261,387,000 | ||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | -2,029,000 | 8,000 | 1,708,000 | 313,000 | |||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 266,000 | 49,000 | 3,000 | 12,000 | 5,000 | -24,000 | 90,000 | 80,000 | 90,000 | 3,140,000 | 7,946,000 | 6,985,000 | 13,805,000 | 10,859,000 | |
| cash flow from financing | -28,234,000 | 19,721,000 | 74,134,000 | 108,953,000 | 941,100,000 | 14,560,947,000 | -24,000 | 791,769,000 | 80,000 | 3,418,663,000 | 3,140,000 | -7,245,000 | 6,993,000 | 774,178,000 | 597,267,000 |
| cash and cash equivalents | |||||||||||||||
| cash | |||||||||||||||
| overdraft | |||||||||||||||
| change in cash |
invitrogen europe limited Credit Report and Business Information
Invitrogen Europe Limited Competitor Analysis
Perform a competitor analysis for invitrogen europe limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in PA4 area or any other competitors across 12 key performance metrics.
invitrogen europe limited Ownership
INVITROGEN EUROPE LIMITED group structure
Invitrogen Europe Limited has no subsidiary companies.
Ultimate parent company
THERMO FISHER SCIENTIFIC INC
#0013877
2 parents
INVITROGEN EUROPE LIMITED
SC084330
invitrogen europe limited directors
Invitrogen Europe Limited currently has 6 directors. The longest serving directors include Mr Euan Cameron (Oct 2018) and Mr Anthony Smith (Nov 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Euan Cameron | United Kingdom | 49 years | Oct 2018 | - | Director |
| Mr Anthony Smith | United Kingdom | 62 years | Nov 2018 | - | Director |
| Mr Syed Ahmed | United Kingdom | 45 years | Mar 2020 | - | Director |
| Mr Syed Ahmed | United Kingdom | 45 years | Mar 2020 | - | Director |
| Ms Alison Starr | United Kingdom | 48 years | Apr 2024 | - | Director |
| Ms Georgina Green | United Kingdom | 55 years | Apr 2024 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
11k
-135%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
22.8b
0%
total assets
22.8b
0%
cash
0
0%
net assets
Total assets minus all liabilities
invitrogen europe limited company details
company number
SC084330
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
August 1983
age
42
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
life technologies overseas limited (May 2001)
gibco overseas limited (January 1990)
accountant
-
auditor
MITCHELL CHARLESWORTH (AUDIT) LIMITED
address
3 fountain drive, inchinnan business park, paisley, renfrewshire, PA4 9RF
Bank
BANK OF AMERICA
Legal Advisor
PINSENT MASONS
invitrogen europe limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to invitrogen europe limited.
invitrogen europe limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for INVITROGEN EUROPE LIMITED. This can take several minutes, an email will notify you when this has completed.
invitrogen europe limited Companies House Filings - See Documents
| date | description | view/download |
|---|
